Reaction profile

The FDA adverse-event record for palpebral oedema

Name: Palpebral oedema - FDA Animal Adverse Reaction
Creator: PlainBreed
License: https://open.fda.gov/license/

13 FDA reports name palpebral oedema, a lower-volume reaction in the CVM extract (VeDDRA 420). Plate stamps and neighbourhood peers follow.

#2363 of 2,481
by report volume (all reactions): 13
reports citing this reaction: 7.7%
death-coded share: Dog
most-affected species

Compiled by PlainBreed

Verify with FDA CVM →

Release-over-release change

What changed in the latest FDA data snapshot

PlainBreed reconstructed the prior snapshot from dated openFDA partitions through 2025 Q4, then compared it with the 2026-07-27 openFDA export. Palpebral oedema has 13 reports now versus 13 in that prior snapshot: 0 the same number of (0.0%).

Report change: +0
Death-coded reports: +0
Death-coded share: +0.0 pts

This compares reported-event counts in two source snapshots. It does not establish a change in real-world risk, product safety, or disease incidence.

Subscribe to Palpebral oedema changes

FDA AER · VeDDRA plate

Code 420 VOL-TRACE

VOL-TRACE · DEATH-PAR · BOTTOM-DECILE · PHOTO-FINISH · SPECIES-DOG · DRUG-LEAD · DESK-WIDE · BOOK-FULL

VOL-TRACE 13 reports
DEATH-PAR 7.7%
BOTTOM-DECILE #2363/2481
PHOTO-FINISH Abnormal digital pulse
SPECIES-DOG Dog · 8
DRUG-LEAD Lufenuron + Milbe… · 3
DESK-WIDE 13 breeds
BOOK-FULL 8/8 fields

Nearest volume peer: Abnormal digital pulse (±0 reports)

Instrument codes from this reaction’s FDA CVM adverse-event extract: volume band, death-coded share, corpus rank, photo-finish peer, lead species, lead drug, breed desk, and book completeness. Not a clinical diagnosis.

Lower-volume neighbourhood around Palpebral oedema

Lower-third volume poles plus nearest peers, not a full reaction corpus board reprint.

FDA AER report volume · neighbourhood around Palpebral oedema

Palpebral oedema: low death-coded share in the FDA AER plate

Signature read: 13 reports place Palpebral oedema in the lower third of FDA AER volume (#2363 of 2,481). Report volume is lower-third scale: 13 named reports in the openFDA extract. Death-coded share is lower-third: 1 of 13 reports (7.7% of named reports). Nearest volume peer: Abnormal digital pulse (±0 reports). Lead species Dog (8). Lead co-reported drug Lufenuron + Milbemycin Oxime (3).

Read these counts as reporting volume, not risk: per our methodology, Lead co-reported drug Lufenuron + Milbemycin Oxime appears in filings alongside this reaction; that is association, not causation. Browse the full reactions index or the about page for how PlainBreed frames FDA CVM extracts.

Species Most Affected

Dog 8

Cat 3

Human 1

Cattle 1

Breeds Most Affected

Spaniel - Irish Water 1

Domestic Shorthair 1

Chihuahua 1

Lhasa Apso 1

Unknown 1

Bulldog 1

Terrier - Boston 1

Dachshund (unspecified) 1

Persian 1

Shih Tzu 1

Associated Drugs

Lufenuron + Milbemycin Oxime 3

Milbemycin Oxime + Spinosad 2

Cyclosporine A 1

Fipronil 1

Ivermectin 1

Robenacoxib 1

Ketamine 1

Vaccinations 1

Xylazine 1

Imidacloprid + Moxidectin 1

Unknown Soap 1

Maropitant Citrate 1

Hyaluronic Acid 1

Tobramycin 1

Antibiotic 1

Artificial Tear Solution 1

Unknown Ocular Solution 1

Cyclosporin Ointment 1

Frunevetmab 1

Doramectin 1

What to do with this reaction

Read how death-coded share differs from a mortality rate before drawing conclusions. Understanding adverse events
Browse the full reaction directory to compare report counts across reaction types. All reactions

A report does not prove a drug caused the reaction; consult a veterinarian before acting on this data.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

openFDA Animal & Veterinary Adverse Events (FDA CVM) for Palpebral oedema (#2363 of 2,481 by report volume); death-coded 7.7%. PlainBreed reaction plate · report volume stamp 13 · vintage 2025.

Informational only. FDA adverse-event reports are voluntary and do not prove causation; consult a veterinarian before acting on them. Verify with FDA CVM →